Contract award · SPE2DS23F0035
8509606737!CARESTART COVID-19 ANTIGEN H
Awarded to ACCESS BIO, INC. · CAGE 3CNE1
Latest reported total obligated
$205.2M
Net observed obligations
$205.2M
Observed contract actions
3
Observed period
FY2023–FY2023
Reported totals are cumulative values from the latest available award record. Observed obligations and actions reflect Mimir's FY2019 onward transaction window and may omit earlier activity.
Award parties and scope
ContractorACCESS BIO, INC.
CAGE3CNE1
Recipient UEIEZEJBJ28AMV4
Ultimate parentACCESS BIO INC
Parent UEIEZEJBJ28AMV4
CustomerDefense Logistics Agency
Performance locationSOMERSET, NEW JERSEY, UNITED STATES
Procurement details
Reported performance startDec 22, 2022
First observed actionDec 22, 2022
Latest observed actionJan 6, 2023
Reported current value$205.2M
Reported potential value$205.2M
PSC6640
NAICS325413 · In-Vitro Diagnostic Substance Manufacturing
CompetitionFULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES
PricingFIRM FIXED PRICE
Annual observed obligations
FY2023
$205.2M
Continue exploring
Ask Mimir about SPE2DS23F0035
Continue with this contract award already in context.
ContinueExplore the full award in Mimir
Open the complete action history and connected analysis in the platform.